Structure-based modeling of the functional HIV-1 intasome and its inhibition

The intasome is the basic recombination unit of retroviral integration, comprising the integrase protein and the ends of the viral DNA made by reverse transcription. Clinical inhibitors preferentially target the DNA-bound form of integrase as compared with the free protein, highlighting the critical requirement for detailed understanding of HIV-1 intasome structure and function. Although previous biochemical studies identified integrase residues that contact the DNA, structural details of protein–protein and protein–DNA interactions within the functional intasome were lacking. The recent crystal structure of the prototype foamy virus (PFV) integrase–viral DNA complex revealed numerous details of this related integration machine. Structures of drug-bound PFV intasomes moreover elucidated the mechanism of inhibitor action. Herein we present a model for the HIV-1 intasome assembled using the PFV structure as template. Our results pinpoint previously identified protein–DNA contacts within the quaternary structure and reveal hitherto unknown roles for Arg20 and Lys266 in DNA binding and integrase function. Models for clinical inhibitors bound at the HIV-1 integrase active site were also constructed and compared with previous studies. Our findings highlight the structural basis for HIV-1 integration and define the mechanism of its inhibition, which should help in formulating new drugs to inhibit viruses resistant to first-in-class compounds.

[1]  A. Engelman,et al.  Multiple Integrase Functions Are Required to Form the Native Structure of the Human Immunodeficiency Virus Type I Intasome* , 1999, The Journal of Biological Chemistry.

[2]  E. Garvey,et al.  Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. , 2008, Antiviral research.

[3]  A. Savarino.  Retrovirology In-silico Docking of Hiv-1 Integrase Inhibitors Reveals a Novel Drug Type Acting on an Enzyme/dna Reaction Intermediate , 2022 .

[4]  F. Bushman,et al.  Identification of discrete functional domains of HIV‐1 integrase and their organization within an active multimeric complex. , 1993, The EMBO journal.

[5]  A. Engelman,et al.  Structural Basis for Functional Tetramerization of Lentiviral Integrase , 2009, PLoS pathogens.

[6]  A. Engelman,et al.  Critical contacts between HIV‐1 integrase and viral DNA identified by structure‐based analysis and photo‐crosslinking , 1997, The EMBO journal.

[7]  Wei Yang,et al.  Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein , 2001, The EMBO journal.

[8]  C. Ferraz,et al.  Evolution of the Gypsy endogenous retrovirus in the Drosophila melanogaster subgroup. , 2000, Molecular biology and evolution.

[9]  Wei Yang,et al.  Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis , 2005, Cell.

[10]  A. Engelman,et al.  Asymmetric Processing of Human Immunodeficiency Virus Type 1 cDNA In Vivo: Implications for Functional End Coupling during the Chemical Steps of DNA Transposition , 2001, Molecular and Cellular Biology.

[11]  D. Langley,et al.  The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. , 2008, Biochemistry.

[12]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[13]  E. Guiot,et al.  Relationship between the Oligomeric Status of HIV-1 Integrase on DNA and Enzymatic Activity* , 2006, Journal of Biological Chemistry.

[14]  Amy S. Espeseth,et al.  Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Engelman,et al.  Subunit-specific Protein Footprinting Reveals Significant Structural Rearrangements and a Role for N-terminal Lys-14 of HIV-1 Integrase during Viral DNA Binding* , 2008, Journal of Biological Chemistry.

[16]  P. Brown,et al.  Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. , 1997, Biochemistry.

[17]  M. Matsuoka,et al.  Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.

[18]  W. Reznikoff,et al.  Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. , 2000, Science.

[19]  Luba Tchertanov,et al.  Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo , 2009, Antimicrobial Agents and Chemotherapy.

[20]  D. Hazuda,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural Intermediate , 2007, Journal of Virology.

[21]  R. Maroun,et al.  Specificity of LTR DNA recognition by a peptide mimicking the HIV-1 integrase α4 helix , 2009, Nucleic acids research.

[22]  Jerome Wielens,et al.  A Three-dimensional Model of the Human Immunodeficiency Virus Type 1 Integration Complex , 2005, J. Comput. Aided Mol. Des..

[23]  F. Bushman,et al.  Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition , 1997, Journal of virology.

[24]  R M Stroud,et al.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Swaminathan,et al.  Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. , 2008, Journal of molecular biology.

[26]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[27]  M. Castroviejo,et al.  HIV-1 integrase crosslinked oligomers are active in vitro , 2005, Nucleic acids research.

[28]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[29]  F. Bushman,et al.  Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase. , 2000, Journal of molecular biology.

[30]  Y. Pommier,et al.  Integration Requires a Specific Interaction of the Donor DNA Terminal 5′-Cytosine with Glutamine 148 of the HIV-1 Integrase Flexible Loop* , 2006, Journal of Biological Chemistry.

[31]  F. Bushman,et al.  HIV-1 cDNA Integration: Requirement of HMG I(Y) Protein for Function of Preintegration Complexes In Vitro , 1997, Cell.

[32]  Kui Gao,et al.  Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes , 2001, The EMBO journal.

[33]  D. Moras,et al.  Structural basis for HIV‐1 DNA integration in the human genome, role of the LEDGF/P75 cofactor , 2009, The EMBO journal.

[34]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[35]  R. Plasterk,et al.  Structure-Based Mutational Analysis of the C-Terminal DNA-Binding Domain of Human Immunodeficiency Virus Type 1 Integrase: Critical Residues for Protein Oligomerization and DNA Binding , 1998, Journal of Virology.

[36]  I. Weber,et al.  Identification of Amino Acids in HIV-1 and Avian Sarcoma Virus Integrase Subsites Required for Specific Recognition of the Long Terminal Repeat Ends* , 2006, Journal of Biological Chemistry.

[37]  Mary A. Bosserman,et al.  Loop202-208 in avian sarcoma virus integrase mediates tetramer assembly and processing activity. , 2007, Biochemistry.

[38]  R. Stroud,et al.  Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs , 2009, Proceedings of the National Academy of Sciences.

[39]  D. Hazuda,et al.  X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platform. , 2000, Journal of molecular biology.

[40]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Mizuuchi,et al.  A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration , 1997, The EMBO journal.

[42]  A. Skalka,et al.  Retroviral integrase domains: DNA binding and the recognition of LTR sequences. , 1991, Nucleic acids research.

[43]  M. Walkinshaw,et al.  Molecular Architecture of the Mos1 Paired-End Complex: The Structural Basis of DNA Transposition in a Eukaryote , 2009, Cell.

[44]  Robert Craigie,et al.  Retroviral DNA integration: reaction pathway and critical intermediates , 2006, The EMBO journal.

[45]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[46]  Christos J. Petropoulos,et al.  Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways , 2009, Journal of Virology.

[47]  Luba Tchertanov,et al.  The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation , 2008, Nucleic acids research.

[48]  D. Esposito,et al.  Sequence specificity of viral end DNA binding by HIV‐1 integrase reveals critical regions for protein–DNA interaction , 1998, The EMBO journal.

[49]  V. Soriano,et al.  Resistance to integrase inhibitors. , 2007, Journal of HIV therapy.

[50]  Alba Chimirri,et al.  Induced‐Fit Docking Approach Provides Insight into the Binding Mode and Mechanism of Action of HIV‐1 Integrase Inhibitors , 2009, ChemMedChem.

[51]  P. Roversi,et al.  Functional and structural characterization of the integrase from the prototype foamy virus , 2008, Nucleic acids research.

[52]  Garrett M Morris,et al.  A dynamic model of HIV integrase inhibition and drug resistance. , 2010, Journal of molecular biology.

[53]  R. Plasterk,et al.  Complementation between HIV integrase proteins mutated in different domains. , 1993, The EMBO journal.